Nuvasive Inc. (NUVA) 58.98 $NUVA
Why NuVasive (NUVA) Could Beat Earnings Estimates Again
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 8:25AM CDT
Positive Earnings ESP coupled with an impressive Zacks Rank has made NuVasive (NUVA) an interesting choice for the investors.
NUVA: 58.98 (-1.03)
NuVasive Shares Up 37.0% Since SmarTrend's Buy Recommendation (NUVA)
Comtex SmarTrend(R) - Thu Jun 09, 1:14PM CDT
SmarTrend identified an Uptrend for NuVasive (NASDAQ:NUVA) on March 4th, 2016 at $43.48. In approximately 3 months, NuVasive has returned 37.01% as of today's recent price of $59.57.
NUVA: 58.98 (-1.03)
NuVasive to Strengthen Spine Service Line with Biotronic Buy
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 7:17AM CDT
NuVasive, Inc. (NUVA) recently entered into a definitive agreement to acquire privately held Biotronic NeuroNetwork.
BSX: 23.02 (-0.30), ICUI: 107.33 (-0.80), BAX: 44.49 (-0.26), NUVA: 58.98 (-1.03)
NuVasive to Acquire Biotronic NeuroNetwork
Marketwired - Mon Jun 06, 3:05PM CDT
SAN DIEGO, CA--(Marketwired - June 06, 2016) -
NUVA: 58.98 (-1.03)
Abaxis (ABAX): Solid Veterinary Show Despite Global Hiccups
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 5:01AM CDT
On Jun 3, 2016, we issued an updated research report on Abaxis, Inc. (ABAX). The stock currently carries a Zacks Rank #4 (Sell).
ICUI: 107.33 (-0.80), ABAX: 45.53 (-1.36), LMAT: 15.03 (-0.06), NUVA: 58.98 (-1.03)
Moving Average Crossover Alert: NuVasive (NUVA)
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 9:55AM CDT
NuVasive, Inc. (NUVA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
NUVA: 58.98 (-1.03)
NuVasive Has Returned 28.3% Since SmarTrend Recommendation (NUVA)
Comtex SmarTrend(R) - Thu Jun 02, 1:01AM CDT
SmarTrend identified an Uptrend for NuVasive (NASDAQ:NUVA) on March 4th, 2016 at $43.48. In approximately 3 months, NuVasive has returned 28.29% as of today's recent price of $55.78.
NUVA: 58.98 (-1.03)
NuVasive Poised on Solid International Sales, Scope in Spine
Zacks Equity Research - Zacks Investment Research - Tue May 31, 6:01AM CDT
On May 30, 2016, we updated our research report on NuVasive, Inc. (NUVA).
BSX: 23.02 (-0.30), ICUI: 107.33 (-0.80), LMAT: 15.03 (-0.06), NUVA: 58.98 (-1.03)
NuVasive to Participate in Investor Events in June 2016
Marketwired - Tue May 31, 6:00AM CDT
SAN DIEGO, CA --(Marketwired - May 31, 2016) - NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, announced today that management will participate in the following investor events in June 2016:
NUVA: 58.98 (-1.03)
After Yesterday's Rally of 2.61% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri May 27, 2:10PM CDT
NuVasive (NASDAQ:NUVA) traded in a range yesterday that spanned from a low of $53.25 to a high of $55.21. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $54.31 on volume of 320,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NUVA: 58.98 (-1.03)
SmarTrend Watching for Potential Pullback in Shares of NuVasive After 2.61% Gain
Comtex SmarTrend(R) - Fri May 27, 2:08PM CDT
NuVasive (NASDAQ:NUVA) traded in a range yesterday that spanned from a low of $53.25 to a high of $55.21. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $54.31 on volume of 320,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NUVA: 58.98 (-1.03)
Ceterix Announces Appointment of Edward Graubart as Vice President, Sales
BusinessWire - Wed May 25, 7:00AM CDT
Ceterix(R) Orthopaedics, Inc., a developer of novel surgical tools that improve a surgeon's ability to perform minimally invasive orthopaedic procedures, today announced that Edward Graubart has joined the company as vice president of sales.
MDSY: 1.50 (-0.04), NUVA: 58.98 (-1.03)
Abaxis (ABAX) Posts Solid Q4 amid International Headwind
Zacks Equity Research - Zacks Investment Research - Wed May 25, 5:28AM CDT
On May 18, 2016, we issued an updated research report on Abaxis, Inc. (ABAX).
ICUI: 107.33 (-0.80), ABAX: 45.53 (-1.36), LMAT: 15.03 (-0.06), NUVA: 58.98 (-1.03)
Zimmer Biomet: Strong Q1, Integration Synergy Continues
Zacks Equity Research - Zacks Investment Research - Mon May 23, 6:39AM CDT
On May 23, 2016, we issued an updated research report on Zimmer Biomet Holdings, Inc. (ZBH).
BSX: 23.02 (-0.30), ICUI: 107.33 (-0.80), ZBH: 119.23 (-0.17), NUVA: 58.98 (-1.03)
NuVasive Launches Next Generation Biologics Technology
Marketwire Canada - Mon May 23, 6:00AM CDT
FDA Cleared Synthetic Bone Graft With Novel Surface Structure That Promotes Bone Formation
NUVA: 58.98 (-1.03)
Why NuVasive (NUVA) Could Beat Earnings Estimates Again
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 8:25AM CDT
Positive Earnings ESP coupled with an impressive Zacks Rank has made NuVasive (NUVA) an interesting choice for the investors.
NUVA: 58.98 (-1.03)
NuVasive Shares Up 37.0% Since SmarTrend's Buy Recommendation (NUVA)
Comtex SmarTrend(R) - Thu Jun 09, 1:14PM CDT
SmarTrend identified an Uptrend for NuVasive (NASDAQ:NUVA) on March 4th, 2016 at $43.48. In approximately 3 months, NuVasive has returned 37.01% as of today's recent price of $59.57.
NUVA: 58.98 (-1.03)
NuVasive to Strengthen Spine Service Line with Biotronic Buy
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 7:17AM CDT
NuVasive, Inc. (NUVA) recently entered into a definitive agreement to acquire privately held Biotronic NeuroNetwork.
BSX: 23.02 (-0.30), ICUI: 107.33 (-0.80), BAX: 44.49 (-0.26), NUVA: 58.98 (-1.03)
NuVasive to Acquire Biotronic NeuroNetwork
Marketwired - Mon Jun 06, 3:05PM CDT
SAN DIEGO, CA--(Marketwired - June 06, 2016) -
NUVA: 58.98 (-1.03)
Abaxis (ABAX): Solid Veterinary Show Despite Global Hiccups
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 5:01AM CDT
On Jun 3, 2016, we issued an updated research report on Abaxis, Inc. (ABAX). The stock currently carries a Zacks Rank #4 (Sell).
ICUI: 107.33 (-0.80), ABAX: 45.53 (-1.36), LMAT: 15.03 (-0.06), NUVA: 58.98 (-1.03)
Moving Average Crossover Alert: NuVasive (NUVA)
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 9:55AM CDT
NuVasive, Inc. (NUVA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
NUVA: 58.98 (-1.03)
NuVasive Has Returned 28.3% Since SmarTrend Recommendation (NUVA)
Comtex SmarTrend(R) - Thu Jun 02, 1:01AM CDT
SmarTrend identified an Uptrend for NuVasive (NASDAQ:NUVA) on March 4th, 2016 at $43.48. In approximately 3 months, NuVasive has returned 28.29% as of today's recent price of $55.78.
NUVA: 58.98 (-1.03)
NuVasive Poised on Solid International Sales, Scope in Spine
Zacks Equity Research - Zacks Investment Research - Tue May 31, 6:01AM CDT
On May 30, 2016, we updated our research report on NuVasive, Inc. (NUVA).
BSX: 23.02 (-0.30), ICUI: 107.33 (-0.80), LMAT: 15.03 (-0.06), NUVA: 58.98 (-1.03)
NuVasive to Participate in Investor Events in June 2016
Marketwired - Tue May 31, 6:00AM CDT
SAN DIEGO, CA --(Marketwired - May 31, 2016) - NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, announced today that management will participate in the following investor events in June 2016:
NUVA: 58.98 (-1.03)
After Yesterday's Rally of 2.61% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri May 27, 2:10PM CDT
NuVasive (NASDAQ:NUVA) traded in a range yesterday that spanned from a low of $53.25 to a high of $55.21. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $54.31 on volume of 320,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NUVA: 58.98 (-1.03)
SmarTrend Watching for Potential Pullback in Shares of NuVasive After 2.61% Gain
Comtex SmarTrend(R) - Fri May 27, 2:08PM CDT
NuVasive (NASDAQ:NUVA) traded in a range yesterday that spanned from a low of $53.25 to a high of $55.21. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $54.31 on volume of 320,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NUVA: 58.98 (-1.03)
Ceterix Announces Appointment of Edward Graubart as Vice President, Sales
BusinessWire - Wed May 25, 7:00AM CDT
Ceterix(R) Orthopaedics, Inc., a developer of novel surgical tools that improve a surgeon's ability to perform minimally invasive orthopaedic procedures, today announced that Edward Graubart has joined the company as vice president of sales.
MDSY: 1.50 (-0.04), NUVA: 58.98 (-1.03)
Abaxis (ABAX) Posts Solid Q4 amid International Headwind
Zacks Equity Research - Zacks Investment Research - Wed May 25, 5:28AM CDT
On May 18, 2016, we issued an updated research report on Abaxis, Inc. (ABAX).
ICUI: 107.33 (-0.80), ABAX: 45.53 (-1.36), LMAT: 15.03 (-0.06), NUVA: 58.98 (-1.03)
Zimmer Biomet: Strong Q1, Integration Synergy Continues
Zacks Equity Research - Zacks Investment Research - Mon May 23, 6:39AM CDT
On May 23, 2016, we issued an updated research report on Zimmer Biomet Holdings, Inc. (ZBH).
BSX: 23.02 (-0.30), ICUI: 107.33 (-0.80), ZBH: 119.23 (-0.17), NUVA: 58.98 (-1.03)
NuVasive Launches Next Generation Biologics Technology
Marketwire Canada - Mon May 23, 6:00AM CDT
FDA Cleared Synthetic Bone Graft With Novel Surface Structure That Promotes Bone Formation
NUVA: 58.98 (-1.03)
